Lataa...
Safety of dipeptidyl peptidase 4 inhibitors: a perspective review
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a relatively new class of oral antihyperglycemic agent that enhance insulin secretion by reducing degradation of endogenous glucagon-like peptide 1. Currently, sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin have been approved by the U...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publications
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4110853/ https://ncbi.nlm.nih.gov/pubmed/25083269 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042098614523031 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|